| Literature DB >> 32571228 |
Jian Wang1, Xiandi Zhu1, Zhihua Xu1, Guangzhao Yang1, Guoqun Mao1, Yuzhu Jia1, Zongyu Xie2, Jing Wang3, Weiqun Ao4.
Abstract
BACKGROUND: The novel coronavirus pneumonia (coronavirus disease 2019, COVID-19) has spread around the world. We aimed to recapitulate the clinical and CT imaging features of COVID-19 and their differences in three age groups.Entities:
Keywords: Age; COVID-19; Pulmonary infection; X-ray computed tomography
Mesh:
Year: 2020 PMID: 32571228 PMCID: PMC7306933 DOI: 10.1186/s12879-020-05154-9
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Flow diagram of enrolled patients
Fig. 2Stacked bars (green) show the age and number distribution of the heavy/critical type of COVID-19. The curve (red) represents the number distribution trend of the heavy/critical type according to the levels of age
Fig. 3Atypical case a: Mild type patient. CT showed a small pGGO in the right middle lobe (arrow), and no abnormality in the remaining lobes. Atypical case b: Mild type patient. Only a small pGGO was detected in the left upper lobe with hale sign (arrow). Typical case c: Moderate type patient. CT showed multiple GGOs in the bilateral lobes with vascular dilatation and halo sign (arrow). Typical case d: Heavy type patient. CT showed diffused GGOs in the bilateral lobes
Fig. 4Typical pGGO case a: Moderate type patient. CT showed multiple pGGOs in the bilateral lung lobes with halo sign (arrow). Some of the lesions were located under the pleura. Typical mGGO case b: Moderate type patient. CT showed a subpleural mGGO within a solitary nodule (arrow)
Fig. 5Typical CT signs. Halo sign a: Moderate type patient. CT showed a pGGO with halo sign in the left low lobe (arrow). reversed halo sign b: Moderate type patient. CT showed a mGGO with reversed halo sign (arrow). Crazy paving sign c: Moderate type patient. CT showed two pGGOs with crazy paving sign in the left low lobe (arrow). Cavity sign d: Moderate type patient. CT showed a pGGO with a small cavity (arrow)
Clinical data characteristics of three age groups of COVID-19 patients
| Groups | All patients ( | Age < 40 Y ( | 40 Y ≤ Age <60 Y ( | 60 Y ≤ Age ( | |||
|---|---|---|---|---|---|---|---|
| CBI | |||||||
| Sex (male, %) | 156 (50.8%) | 53 (51%) | 72 (52.6%) | 31 (47%) | 0.806 | 0.612 | 0.456 |
| Age (M ± SD, Y) (Rang, Y) | 46.2 ± 17.11 (1 ~ 89) | 2.3 ± 8.35 (1 ~ 39) | 49.3 ± 5.35 (40 ~ 59) | 69.3 ± 8.51 l(60 ~ 89) | / | / | / |
| HD | |||||||
| Hypertension | 31 (10.1%) | 0 | 16 (11.7%) | 15 (22.7%) | <0.001 | <0.001 | 0.040 |
| Diabetes | 15 (4.9%) | 0 | 9 (6.6%) | 6 (9.1%) | 0.020 | 0.007 | 0.721 |
| Hepatitis B | 8 (2.6%) | 1 (1%) | 7 (5.1%) | 0 | 0.156 | 1.000 | 0.145 |
| COPD | 3 (1%) | 0 | 0 | 3 (4.5%) | 1.000 | 0.058 | 0.110 |
| Clinical symptoms | |||||||
| Fever | 301 (98%) | 100 (96.2%) | 135 (98.5%) | 66 (100%) | 0.447 | 0.274 | 0.820 |
| Cough | 239 (77.9%) | 79 (76%) | 101 (73.7%) | 59 (89.4%) | 0.692 | 0.029 | 0.010 |
| Fatigue | 51 (16.6%) | 13 (12.5%) | 23 (16.8%) | 15 (22.7%) | 0.355 | 0.080 | 0.310 |
| Sore throat | 37 (12.1%) | 14 (13.5%) | 14 (10.2%) | 9 (13.6%) | 0.453 | 0.955 | 0.472 |
| Chest tightness or pain | 34 (11.1%) | 6 (5.8%) | 12 (8.8%) | 16 (24.2%) | 0.382 | <0.001 | 0.003 |
| Dizziness or pain | 28 (9.1%) | 8 (7.7%) | 13 (9.5%) | 7 (10.6%) | 0.624 | 0.514 | 0.802 |
| Aching muscles | 27 (8.8%) | 5 (4.8%) | 15 (10.9%) | 7 (10.6%) | 0.087 | 0.258 | 0.941 |
| Hyperpnea | 21 (6.8%) | 3 (2.9%) | 10 (7.3%) | 8 (12.1%) | 0.133 | 0.039 | 0.258 |
| Nasal stuffiness | 20 (6.5) | 8 (7.7%) | 11 (8%) | 1 (1.5%) | 0.923 | 0.161 | 0.127 |
| Others# | 8 (2.6%) | 2 (1.9%) | 3 (2.2%)) | 3 (4.5%) | 1.000 | 0.603 | 0.627 |
| LE | |||||||
| CRP increase | 182 (59.3%) | 47 (45.2%) | 93 (67.9%) | 42 (63.6%) | <0.001 | 0.019 | 0.548 |
| LY% abnormal | 148 (48.2%) | 35 (33.7%)6↑ | 71 (51.8%)1↑ | 42 (63.6%) | 0.005 | <0.001 | 0.113 |
| NEUT% abnormal | 95 (30.9%) | 21 (20.2%)5↓ | 43 (31.4%)3↓ | 31 (47%) | 0.051 | <0.001 | 0.031 |
| MO% abnormal | 70 (22.8%) | 31 (29.8%)2↓ | 33 (24.1%) | 6 (9.1%) | 0.319 | 0.001 | 0.011 |
| WBC% abnormal | 60 (19.5%) | 19 (18.3%)2↑ | 21 (15.3%)4↑ | 20 (30.3%)9↑ | 0.543 | 0.069 | 0.013 |
| Clinical types | 0.002 | <0.001 | 0.015 | ||||
| Mild/Moderate | 259 (84.6%) | 100 (96.2%) | 114 (83.2%) | 45 (68.2%) | |||
| Severe/Critical | 48 (15.6%) | 4 (3.8%) | 23 (16.8%) | 21 (31.8%) | |||
| HEE | 114 (37.1%) | 49 (47.1%) | 56 (40.9%) | 9 (13.6%) | 0.333 | <0.001 | <0.001 |
Note: Y years, G1 Age<40 Y, G2 40 Y ≤ Age<60 Y, G3 60 Y ≤ Age, CBI Clinical baseline information, COPD chronic obstructive pulmonary disease, HD History of disease, LE laboratory examination; CRP: C-reactive protein (normal: 0 ~ 10 mg/); WBC: white blood cell (normal: 3.5 ~ 9.5 × 109), Ly lymphocyte (normal: 20% ~ 40%), Mo monocyte (normal: 3 ~ 10%), NEUT neutrophil (normal: 40% ~ 75%), HEE history of epidemiological exposure, Others* Major diseases or surgical history, Others# diarrhoea or vomiting
CT characteristics of three age groups of COVID-19 patients
| Groups | All patients ( | Age < 40 Y ( | 40 Y ≤ Age <60 Y ( | 60 Y ≤ Age ( | |||
|---|---|---|---|---|---|---|---|
| CT Findings (LW) | |||||||
| Location | <0.001 | <0.001 | 0.240 | ||||
| One lobe or Two lobes | 85 (27.7%) | 58 (55.8%) | 28 (20.4%) | 9 (13.6%) | |||
| Multiple lobes | 222 (72.3%) | 46 (44.2%) | 109 (79.6%) | 57 (86.4%) | |||
| Number | <0.001 | <0.001 | 1.000 | ||||
| One or two | 31 (10.1%) | 23 (22.1%) | 5 (3.6%) | 3 (4.5%) | |||
| More | 276 (89.9%) | 81 (77.9%) | 132 (96.4%) | 63 (95.5%) | |||
| Subpleural lesions | 289 (94.1%) | 90 (86.5%) | 135 (98.5%) | 64 (97%) | <0.001 | 0.023 | 0.830 |
| Shape | |||||||
| pGGO | 276 (89.9%) | 99 (95.2%) | 123 (89.8%) | 54 (81.8%) | 0.123 | 0.005 | 0.112 |
| mGGO | 191 (62.2%) | 60 (57.7%) | 85 (62%) | 46 (69.7%) | 0.494 | 0.115 | 0.286 |
| Sign | |||||||
| Halo sign | 254 (82.7%) | 86 (82.7%) | 114 (83.2%) | 54 (81.8%) | 0.915 | 0.884 | 0.806 |
| Reversed halo sign | 38 (12.4%) | 8 (7.7%) | 22 (16.1%) | 8 (12.1%) | 0.051 | 0.335 | 0.459 |
| Crazy paving sign | 117 (38.1%) | 18 (17.3%) | 66 (48.2%) | 33 (50%) | <0.001 | <0.001 | 0.808 |
| Cavity sign | 21 (6.8%) | 3 (2.9%) | 11 (8.3%)) | 8 (12.1%) | 0.091 | 0.039 | 0.348 |
| Organizational involvement | |||||||
| Vascular dilatation | 249 (81.1%) | 77 (74%) | 112 (81.8%) | 60 (90.9%) | 0.053 | 0.002 | 0.089 |
| Bronchodilatation | 146 (47.6%) | 38 (36.5%) | 69 (50.4%) | 39 (59.1%) | 0.032 | 0.004 | 0.243 |
| CT Findings (MW) | |||||||
| Pleural thickening* | 36 (11.7%) | 4 (3.8%) | 21 (15.3%) | 11 (16.7%) | 0.004 | 0.004 | 0.806 |
| Pleural effusion* | 15 (4.9%) | 4 (3.8%) | 6 (4.4%) | 5 (7.6%) | 1.000 | 0.480 | 0.541 |
| Lymphadenectasis | 13 (4.2%) | 3 (2.9%) | 5 (3.6%) | 5 (7.6%) | 1.000 | 0.300 | 0.144 |
Note: G1 Age<40 Y, G2 40 Y ≤ Age<60 Y, G3 60 Y ≤ Age, LW lung window, MW mediastinal window, pGGO pure ground-glass opacity, mGGO mixed ground-glass opacity, * All but one patients had mild pleural thickening or a little effusion (the only one case had moderate pleural effusion)
Relationship with the severity of COVID-19 and underlying diseases
| UD* Clinical types | Hypertension | Diabetes | Hepatitis B | COPD | NUD | ||||
|---|---|---|---|---|---|---|---|---|---|
| Mild/Moderate | 13 | 4 | 5 | 0 | 243 | <0.001 | <0.001 | 0.019 | <0.001 |
| Severe/Critical | 18 | 11 | 3 | 3 | 20 |
UD* underlying diseases, patients with 1–3 basic diseases, NUD No underlying diseases, P1 Hypertension & NUD, P2 Diabetes & NUD, P3 Hepatitis B & NUD, P4 COPD & NUD
Fig. 6Stacked bars show the distribution of number of lesions on CT images for three age groups. Patients were grouped by age: (Group 1: < 40 years old; n = 104), (Group 2:40 ≤ age < 60 years old; n = 137), (Group 3: ≥ 60 years old; n = 66)